Santhera Pharmaceuticals Holding AG (SANN) - Total Assets

Latest as of June 2025: CHF130.77 Million CHF ≈ $165.33 Million USD

Based on the latest financial reports, Santhera Pharmaceuticals Holding AG (SANN) holds total assets worth CHF130.77 Million CHF (≈ $165.33 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See SANN total equity for net asset value and shareholders' equity analysis.

Santhera Pharmaceuticals Holding AG - Total Assets Trend (2006–2024)

This chart illustrates how Santhera Pharmaceuticals Holding AG's total assets have evolved over time, based on quarterly financial data.

Santhera Pharmaceuticals Holding AG - Asset Composition Analysis

Current Asset Composition (December 2024)

Santhera Pharmaceuticals Holding AG's total assets of CHF130.77 Million consist of 49.7% current assets and 50.3% non-current assets.

Asset Category	Amount (CHF)	% of Total Assets
Cash & Equivalents	CHF22.59 Million	26.8%
Accounts Receivable	CHF13.88 Million	9.1%
Inventory	CHF17.53 Million	11.5%
Property, Plant & Equipment	CHF2.57 Million	1.7%
Intangible Assets	CHF68.95 Million	45.2%
Goodwill	CHF0.00	0.0%

Asset Composition Trend (2006–2024)

This chart illustrates how Santhera Pharmaceuticals Holding AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Santhera Pharmaceuticals Holding AG.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Santhera Pharmaceuticals Holding AG's current assets represent 49.7% of total assets in 2024, a decrease from 78.9% in 2006.
Cash Position: Cash and equivalents constituted 26.8% of total assets in 2024, down from 77.4% in 2006.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 45.0% of total assets, an increase from 19.0% in 2006.
Asset Diversification: The largest asset category is intangible assets at 45.2% of total assets.

Santhera Pharmaceuticals Holding AG Competitors by Total Assets

Key competitors of Santhera Pharmaceuticals Holding AG based on total assets are shown below.

Company	Country	Total Assets
Argen-X F:1AE	Germany	€7.18 Billion
Tubize-Fin BR:TUB	Belgium	€1.93 Billion
BrightGene Bio Medical Technology C SHG:688166	China	CN¥5.38 Billion
Dashenlin Pharm Grp Co Ltd SHG:603233	China	CN¥26.08 Billion
Staidson Beijing Biopharma SHE:300204	China	CN¥1.26 Billion
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	China	CN¥6.64 Billion
Ardelyx Inc NASDAQ:ARDX	USA	$486.17 Million
Xiangxue Pharmaceutical SHE:300147	China	CN¥7.36 Billion

Santhera Pharmaceuticals Holding AG - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	1.02	0.63	1.22
Quick Ratio	0.57	0.52	0.99
Cash Ratio	0.00	0.00	0.00
Working Capital	CHF1.02 Million	CHF-19.41 Million	CHF6.58 Million

Santhera Pharmaceuticals Holding AG - Advanced Valuation Insights

This section examines the relationship between Santhera Pharmaceuticals Holding AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	6.56
Latest Market Cap to Assets Ratio	1.60
Asset Growth Rate (YoY)	39.1%
Total Assets	CHF152.49 Million
Market Capitalization	$244.59 Million USD

Valuation Analysis

Above Book Valuation: The market values Santhera Pharmaceuticals Holding AG's assets above their book value (1.60x), reflecting positive investor sentiment about the company's future prospects.

Rapid Asset Growth: Santhera Pharmaceuticals Holding AG's assets grew by 39.1% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Santhera Pharmaceuticals Holding AG (2006–2024)

The table below shows the annual total assets of Santhera Pharmaceuticals Holding AG from 2006 to 2024.

Year	Total Assets	Change
2024-12-31	CHF152.49 Million ≈ $192.79 Million	+39.09%
2023-12-31	CHF109.63 Million ≈ $138.60 Million	+72.03%
2022-12-31	CHF63.73 Million ≈ $80.57 Million	-30.06%
2021-12-31	CHF91.12 Million ≈ $115.20 Million	+2.74%
2020-12-31	CHF88.69 Million ≈ $112.12 Million	-22.92%
2019-12-31	CHF115.05 Million ≈ $145.46 Million	+4.31%
2018-12-31	CHF110.29 Million ≈ $139.44 Million	+0.47%
2017-12-31	CHF109.78 Million ≈ $138.79 Million	+20.91%
2016-12-31	CHF90.79 Million ≈ $114.79 Million	-22.50%
2015-12-31	CHF117.15 Million ≈ $148.11 Million	+410.58%
2014-12-31	CHF22.95 Million ≈ $29.01 Million	+135.67%
2013-12-31	CHF9.74 Million ≈ $12.31 Million	-46.75%
2012-12-31	CHF18.29 Million ≈ $23.12 Million	-64.86%
2011-12-31	CHF52.03 Million ≈ $65.79 Million	-33.94%
2010-12-31	CHF78.77 Million ≈ $99.58 Million	-16.83%
2009-12-31	CHF94.70 Million ≈ $119.73 Million	-16.15%
2008-12-31	CHF112.95 Million ≈ $142.80 Million	-21.66%
2007-12-31	CHF144.18 Million ≈ $182.28 Million	-11.22%
2006-12-31	CHF162.39 Million ≈ $205.31 Million	--

About Santhera Pharmaceuticals Holding AG

SW:SANN Switzerland Biotechnology

Market Cap

$305.63 Million

CHF241.74 Million CHF

Market Cap Rank

#15771 Global

#167 in Switzerland

Share Price

CHF17.00

Change (1 day)

-5.87%

52-Week Range

CHF9.58 - CHF18.54

All Time High

CHF1070.00